Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06223009 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Healthy Volunteer Burn Therapy Study
A Phase 1 study, sponsored by Neomatrix Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT06223009: Completed Phase 1 study, sponsored by Neomatrix Therapeutics.
NCT06223009 is a Phase 1 study that has completed, run by Neomatrix Therapeutics. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06223009, a Phase 1 study, has completed, sponsored by Neomatrix Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a Phase 1, single-center, randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety of an investigational drug to treat burns. Participants will be healthy male and female adults. The study will consist of a screening period, inpatient dosing and observation period and safety follow-up. Participants will receive 1 intravenous dose of the investigational drug or placebo. Duration of participation will be approximately 38 days, which includes a maximum of a 30 day screening period and a study period of approximately 8 days.
Interventions
- OTHER Placebo
- DRUG cNP8
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-01-30 |
| Est. Completion | 2024-07-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06223009
The ClinicalTrials.gov registry entry for NCT06223009 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neomatrix Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06223009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06223009 about?
NCT06223009 is a clinical study titled "Phase 1 Healthy Volunteer Burn Therapy Study". This is a Phase 1, single-center, randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety of an investigational drug to treat burns. Participants will be healthy male and female adults. The study will consist of a screening period, inpatient dosing and observation p...
What is the current status of trial NCT06223009?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2024-01-30. Estimated completion is 2024-07-23.
What interventions are being tested in trial NCT06223009?
The interventions under investigation include: Placebo (OTHER), cNP8 (DRUG).
Who is sponsoring clinical trial NCT06223009?
This trial is sponsored by Neomatrix Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.